Skip to main content

Table 1 Baseline characteristicsa in those receiving combination therapy with an α-blocker plus an antimuscarinic

From: A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

  Overall population
(N = 1891)b
FDC (N = 665) Concomitant therapy (N = 1226)
Age at index date, mean (SD) 71.95 (9.55) 70.46 (9.11) 72.77 (9.68)
Age at index date, N (%)
 45–64 years 417 (22.1) 172 (25.9) 245 (20.0)
 65–74 years 654 (34.6) 260 (39.1) 394 (32.1)
 ≥75 years 820 (43.4) 233 (35.0) 587 (47.9)
Polypharmacy,c mean (SD) 3.38 (3.33) 4.35 (3.18) 5.54 (3.40)
Polypharmacy,c N (%)
 0 420 (22.2) 223 (33.5) 197 (16.1)
 1–3 729 (38.6) 274 (41.2) 455 (37.1)
 4–5 303 (16.0) 79 (11.9) 224 (18.3)
 6–8 278 (14.7) 68 (10.2) 210 (17.1)
 ≥9 161 (8.5) 21 (3.2) 140 (11.4)
Prescriber at index date, N (%)
 Urologist 726 (38.4) 456 (68.6) 270 (22.0)
 GP 931 (49.2) 130 (19.6) 801 (65.3)
 Other 234 (12.4) 79 (11.9) 155 (12.6)
Prior treatment, N (%)
 Any combination 479 (25.3) 230 (34.6) 249 (20.3)
 α-blocker + antimuscarinic 298 (15.8) 121 (18.2) 177 (14.4)
 α-blocker 1668 (88.2) 549 (82.6) 1119 (91.3)
 Antimuscarinic 989 (52.3) 237 (35.6) 752 (61.3)
 5-ARI 157 (8.3) 88 (13.2) 69 (5.6)
Concomitant therapy, N (%)
 Both drugs initiated on the same date 341 (27.8)
 Both drugs initiated within 30 days 885 (72.2)
  1. 5-ARI 5α-reductase inhibitor, FDC fixed-dose combination, GP general practitioner, SD standard deviation
  2. aAt index date
  3. bThe overall population comprised men receiving FDC or concomitant therapy of an α-blocker and an antimuscarinic
  4. cNumber of drugs (classified by Anatomical Therapeutic Chemical code) prescribed, excluding those approved for the treatment of LUTS/BPH.